Drugs / POS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06468527 | Jun 2024 → Jun 2025 | cystic fibrosis | Kors van der Ent | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POS | “Diponecaftor is a triple combination of DIR/POS/NES.” NCT06468527 ↗ |
| Route | Oral | “The combination therapy will be administered orally during 8 weeks.” NCT06468527 ↗ |